Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2009 - $15,200
Dec 2010 - 19 pages - $99
Jan 2010 - $75
Nov 2010 - 40 pages - $500
Aug 2011 - 8 pages - $75
Aug 2011 - 7 pages - $75
Nov 2010 - 26 pages - $125
Aug 2011 - 7 pages - $75
Aug 2011 - 7 pages - $75
Aug 2011 - 8 pages - $75
Your selection
Browse By
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us